Skip to main content
EWBC $136.60 +0.47%
EWBC logo

EWBC · East West Bancorp Inc

Track EWBC — free
$136.60 +0.64 (+0.47%) At close · Aug 14
Market Cap
$18.72B
Shares
137.01M
All earnings calls

Earnings call · FY2025 Q4

East West Bancorp Inc Q4 FY2025 Earnings Call

East West Bancorp Inc Q4 FY2025 Earnings Call

Concluded Jan 22, 2026 Audio replay
Jan 22, 2026 45:57 79 turns
Period
FY2025 Q4
Runtime
45:57
Sources
5 artifacts

Executive readout · one minute

What matters this quarter

East West Bancorp reported record full-year 2025 net income of $1.3 billion ($9.52 diluted EPS) with revenue up 12% year-over-year, while announcing a 33% dividend increase to $0.80 per quarter.

Loan Growth and Diversification 18 Capital and Capital Returns 15 Fee Income Expansion 13 Rate Sensitivity and Securities Portfolio 10 Asset Quality and Credit 8 Deposit Growth and Funding 7

Management tone

Confident

Net tone +78 · low hedging

Grounding quotes
  • “2025 was another record-breaking year for EastWest. Our highlights include new full-year record levels for multiple categories, including revenue, net interest income, fees, non-interest income, earnings per share, loans, and deposits.”
  • “East-West continues to deliver industry-leading efficiency. The fourth quarter efficiency ratio was 34.5%.”
  • “we reported tangible book value per share growth of 17% and generated a 17% return on tangible common equity”
  • “asset quality metrics will continue to broadly outperform the industry”

Forward guidance

9 guided metrics

Management's latest ranges and targets are included below.

Research coverage

5 live sources

Switch sources without leaving this page or losing your listening position.

Net income · derived Q4 $356.27M +21.5% YoY

Research materials

Open the source you need; every reader stays inside this workspace.

Key takeaways

What improved, and what deserves a closer read.

Constructive signals

  • Full-year revenue grew 12% to $2,932 million, with net income up 14% to $1,325 million and diluted EPS up 14% to $9.52
  • End-of-period loans and deposits each grew 6% year-over-year, led by C&I and residential mortgage lending
  • Fee income grew 12% in 2025 to record levels, driven by wealth management, derivatives, foreign exchange, deposit and lending fees
  • Fourth quarter efficiency ratio was 34.5%, described as industry-leading
  • Net charge-offs of 8 bps in Q4 and 11 bps for full year 2025; criticized loans declined to 2.01% from 2.14% sequentially
  • Quarterly dividend raised 33% to $0.80 per share; tangible book value per share grew 17% and ROTCE was 17%

Risks & pressure points

  • Lending spreads compressed by approximately 0.25 percentage points over the past year due to competitive pressure
  • Provision for credit losses of $30 million in Q4; full-year 2026 net charge-offs projected at 20-30 bps, well above 11 bps in 2025
  • 2026 operating non-interest expense expected to grow 7%-9%, faster than recent revenue growth assumptions
  • 2026 outlook assumes three additional Fed rate cuts of 75 bps, which is expected to pressure NII beyond near-term benefits
  • Return on average tangible common equity declined 6 bps year-over-year to 16.99%

Key moments

Jump directly to management's words in the synchronized transcript.

Forward guidance

From the 8-K filed Jan 22, 2026.

Metric Guided
End of Period Loans Initiated
FY 2026
5% – 7%
Total Operating Noninterest Expense Initiated
FY 2026
7% – 9%
Net Interest Income Initiated
FY 2026
5% – 7%
Effective tax rate Initiated
FY 2026
22% – 23%
Amortization of tax credit and CRA investment expense Initiated
FY 2026
$85M – $95M

Guidance from the call

Stated verbally and extracted from the transcript.

Metric Guided
Total loan growth
for the year
5% – 7%
Total operating non-interest expense growth
2026
7% – 9%
Net interest income growth
2026
5% – 7%
Common stock dividend
first quarter of 2026
$0.80

Quarter detail

How the reported period landed and where the business moved.

Capital returned

Buybacks · derived
$1.04M
Dividend / share
$0.80
Full-screen source Call document